Gilead Sciences Inc (NASDAQ:GILD) on Thursday reported adjusted earnings of $2.47 per share, beating the consensus of $2.13.

GILD is in positive territory. Get the complete picture here

The U.S. drug maker reported revenues of $7.77 billion, beating the consensus of $7.45 billion.

Product sales decreased 2% to $7.3 billion, primarily driven by lower Veklury (remdesivir) and Cell Therapy sales, partially offset by higher HIV and Livdelzi (seladelpar) sales.

"With multiple potential product launches in 2026, the strongest clinical pipeline in Gilead's history, and no major loss of exclusivity expected until 2036, we are well-positioned to drive positive impact for patients and continued growth of our business," said Daniel O'Day, Gilead's Chairman and CEO.

HIV product sales increased 4% to $5.3 billion. Liver Disease portfolio sales increased 12% ...